Replimune Group (NASDAQ:REPL) Shares Up 3.8% on Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL)’s stock price shot up 3.8% on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $14.00 to $17.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Replimune Group traded as high as $11.50 and last traded at $11.49. 89,276 shares traded hands during trading, a decline of 92% from the average session volume of 1,124,411 shares. The stock had previously closed at $11.07.

A number of other research firms have also recently weighed in on REPL. Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a report on Thursday, June 6th. Barclays lifted their price target on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a report on Monday, September 16th. Finally, Roth Mkm initiated coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $16.80.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The transaction was disclosed in a document filed with the SEC, which is available through this link. 20.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REPL. Millennium Management LLC raised its position in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after acquiring an additional 1,679,553 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Rafferty Asset Management LLC boosted its holdings in shares of Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after purchasing an additional 276,596 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Replimune Group in the first quarter valued at approximately $1,088,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

The stock has a market cap of $760.40 million, a price-to-earnings ratio of -3.44 and a beta of 1.22. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The firm has a fifty day moving average of $10.31 and a 200 day moving average of $8.50.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10. As a group, sell-side analysts forecast that Replimune Group, Inc. will post -3.11 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.